Effect of Hepatic Impairment on M2951 (BTK Inhibitor) PK

Overview

This study is to investigate the pharmacokinetic (PK) and safety of M2951 (Bruton's tyrosine kinase [BTK] inhibitor) in participants with different degrees of hepatic impairment compared to participants with normal hepatic function.

Full Title of Study: “Phase I Open-label, Single Dose Study to Investigate the Effect of Hepatic Impairment on the PK of Evobrutinib (M2951)”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Non-Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: May 16, 2021

Interventions

  • Drug: M2951 (BTK inhibitor)
    • Participants will receive a single oral dose of M2951 (BTK inhibitor).

Arms, Groups and Cohorts

  • Experimental: Group 1: Normal Hepatic Function
    • Healthy participants who have normal hepatic function with sex, age (± 10 years; >= 18 years old and =< 79 years old), and weight (± 10 percent; >= 50 kilogram (kg) and =< 120 kg) matching with the mild and moderate hepatic impairment cohorts will receive single oral dose of M2951 (BTK inhibitor).
  • Experimental: Group 2: Mild Hepatic Impairment
    • Participants with mild hepatic impairment based on Child-Pugh Class A score of 5 or 6 will receive single oral dose of M2951 (BTK inhibitor).
  • Experimental: Group 3: Moderate Hepatic Impairment
    • Participants with moderate hepatic impairment based on Child-Pugh Class B score of 7 to 9 will receive single oral dose of M2951 (BTK inhibitor).

Clinical Trial Outcome Measures

Primary Measures

  • Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC 0-inf) of M2951 (BTK inhibitor)
    • Time Frame: Pre-dose up to 32 hours post-dose
  • Maximum Observed Plasma Concentration (Cmax) of M2951 (BTK inhibitor)
    • Time Frame: Pre-dose up to 32 hours post-dose

Secondary Measures

  • Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
    • Time Frame: Day 1 up to Day 6
  • Number of Participants With Clinically Significant Change From Baseline in Vital Signs, Laboratory Parameters and Electrocardiogram Findings
    • Time Frame: Day 1 up to Day 6
    • Number of participants with clinically significant change from baseline in vital signs, laboratory parameters and electrocardiogram findings will be reported.
  • Time to Reach Maximum Plasma Concentration (Tmax) of M2951 (BTK inhibitor)
    • Time Frame: Pre-dose up to 32 hours post-dose
  • Apparent Elimination Half Life (t1/2) of M2951 (BTK inhibitor)
    • Time Frame: Pre-dose up to 32 hours post-dose
  • Area Under The Plasma Concentration-Time Curve From Time Zero to Time 12 Hours After M2951 (BTK inhibitor) Administration (AUC0-12)
    • Time Frame: Pre-dose up to 12 hours
  • Area Under the Plasma Concentration-Time Curve From Time Zero to Time 24 Hours After M2951(BTK inhibitor) Administration (AUC0-24)
    • Time Frame: Pre-dose up to 24 hours post-dose
  • Area Under the Plasma Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUC0-t) of M2951 (BTK inhibitor)
    • Time Frame: Pre-dose up to 32 hours post-dose
  • Apparent Total Body Clearance (CL/f) of M2951 (BTK inhibitor)
    • Time Frame: Pre-dose up to 32 hours post-dose
  • Apparent Volume of Distribution During Terminal Phase (VZ/f) of M2951 (BTK inhibitor)
    • Time Frame: Pre-dose up to 32 hours post-dose
  • Fraction of Unbound Drug (M2951 [BTK inhibitor]) in the Plasma (fu)
    • Time Frame: Pre-dose up to 32 hours post-dose
  • Area Under Plasma Concentration for Unbound Drug (M2951 [BTK inhibitor]) From Time Zero to Infinity (AUC0-inf-u)
    • Time Frame: Pre-dose up to 32 hours post-dose
  • Maximum Observed Plasma Concentration of Unbound M2951 (BTK inhibitor) (Cmax, u)
    • Time Frame: Pre-dose up to 32 hours post-dose
  • Apparent Oral Clearance (CL,u/F) of Unbound M2951 (BTK inhibitor)
    • Time Frame: Pre-dose up to 32 hours post-dose

Participating in This Clinical Trial

Inclusion Criteria

  • Participants with normal hepatic function only will be overtly healthy as determined by medical evaluation, including no clinically significant abnormality identified on physical examination or laboratory evaluation and no active clinically significant disorder, condition, infection or disease that would pose a risk to participant safety or interfere with the study evaluation, procedures, or completion OR – Participants with moderately impaired hepatic function only will be considered to have moderately (Child-Pugh class B and confirmed liver cirrhosis) impaired hepatic function and has been clinically stable for at least 1 month prior to Screening OR – Participants with mildly impaired hepatic function only will be considered to have mildly (Child-Pugh class A and confirmed liver cirrhosis) impaired hepatic function and has been clinically stable for at least 1 month prior to Screening – Have a body weight within 50.0 and 120.0 kilogram (kg) and body mass index (BMI) within the range 19.0 and 36.0 kilogram per square meter (kg/m^2) – Female participants are not pregnant or breastfeeding, and at least one of the following conditions applies – Not a woman of childbearing potential (WOCBP) – Other protocol defined inclusion criteria could apply Exclusion Criteria:

  • Clinical history of autoimmune disorder with hepatic influence (Hashimoto thyroiditis and rheumatic diseases allowed) – History of any malignancy – Diseases and surgeries of the gastrointestinal tract, which could influence the gastrointestinal anatomy and mobility. Prior history of cholecystectomy or inflammatory bowel disease, and any clinically relevant surgery within 6 months prior to Screening – History of chronic or recurrent acute infection or any bacterial, viral, parasitic or fungal infections within 30 days prior to Screening and at any time between Screening and admission, or hospitalization due to infection within 6 months prior to Screening – History of shingles within 12 months prior to Screening – History of drug hypersensitivity, ascertained or presumptive allergy/hypersensitivity to the active drug substance and/or formulation ingredients; history of serious allergic reactions leading to hospitalization or any other hypersensitivity reaction in general, which may affect the safety of the participant and/or outcome of the trial per the Investigator's discretion – Participants with impaired hepatic function will be excluded who had Primary and secondary biliary cirrhosis. – Participants with impaired hepatic function will be excluded with Clinical evidence of severe ascites. – Participants with impaired hepatic function will be excluded with Hepatic encephalopathy Grade greater than 1 – Other protocol defined exclusion criteria could apply

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 79 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Medical Responsible, Study Director, Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.